Cara N. Cacioppo, Brian L. Egleston, Dominique Fetzer, Colleen Burke Sands, Syeda A. Raza, Neeraja Reddy Malleda, Elisabeth McCarty Wood, India Rittenburg, Julianne Childs, David Cho, Martha Hosford, Tina Khair, Jamil Khatri, Lydia Komarnicky, Trina Poretta, Fahd Rahman, Satish Shah, Linda J. Patrick‐Miller, Susan M. Domchek, Angela R. Bradbury

To examine the benefit of telehealth over current delivery options in oncology practices without genetic counselors. Participants meeting cancer genetic testing guidelines were recruited to this multi-center, randomized trial comparing uptake of genetic services with remote services (telephone or videoconference) to usual care in six predominantly community practices without genetic counselors. The primary outcome was the composite uptake of genetic counseling or testing. Secondary outcomes compare telephone versus videoconference services. 147 participants enrolled and 119 were randomized. Eighty percent of participants in the telehealth arm had genetic services as compared to 16% in the usual care arm (OR 30.52, p < 0.001). Five genetic mutation carriers (6.7%) were identified in the telehealth arm, compared to none in the usual care arm. In secondary analyses, factors associated with uptake were lower anxiety (6.77 vs. 8.07, p = 0.04) and lower depression (3.38 vs. 5.06, p = 0.04) among those who had genetic services. There were no significant differences in change in cognitive or affective outcomes immediately post-counseling and at 6 and 12 months between telephone and videoconference arms. Telehealth increases uptake of genetic counseling and testing at oncology practices without genetic counselors and could significantly improve identification of genetic carriers and cancer prevention outcomes.